{"id":851,"date":"2023-03-10T15:08:50","date_gmt":"2023-03-10T15:08:50","guid":{"rendered":"https:\/\/newsletters.aans.org\/tumor\/?page_id=851"},"modified":"2023-03-10T15:08:50","modified_gmt":"2023-03-10T15:08:50","slug":"clinical-trials-and-registries","status":"publish","type":"page","link":"https:\/\/newsletters.aans.org\/tumor\/tumor-news-spring-2023\/clinical-trials-and-registries\/","title":{"rendered":"Clinical Trials and Registries"},"content":{"rendered":"

Chair, Co-Chair<\/strong>: Brad Elder, MD, and Gavin Dunn, MD\"\"\"\"
\nMembers:<\/strong> Dan Cahill, MD, Melanie Hayden Gephart, MD,
\nMark Linskey, MD, Timothy Smith, MD, Andrew Sloan, MD,
\nand Michael Vogelbaum, MD<\/p>\n

\u00a0<\/strong><\/p>\n

From the \u201cClinical Trials and Registries\u201d sub-committee, we are excited to provide updates on important tumor registry and highlight clinical trial activity.<\/p>\n

Most importantly, we prepared a survey to be circulated among all tumor neurosurgeons regarding the NeuroPoint Alliance (NPA)and national clinical trial consortia. This survey focuses on<\/p>\n

helping the Tumor Section identify ways to strengthen neurosurgeon involvement in these national committees. We are targeting maximal engagement and kept the survey short. If you would like to participate, please email Brad Elder at brad.elder@osumc.edu<\/a><\/p>\n

 <\/p>\n

Alliance for Clinical Trials in Oncology<\/em><\/p>\n

In this report, we highlight an Alliance study, \u201cSingle Fraction Stereotactic Radiosurgery Compared with Fractionated Stereotactic Radiosurgery in Treating Patients with Resected Metastatic Brain Disease.\u201d Inclusion criteria are patients with resected brain metastasis from a non-CNS primary site and three or fewer unresected brain metastases at the time of screening. Unresected tumors must measure < 4.0 cm in maximal diameter. One (and only one) brain metastasis must have been completely (GTR) resected within 30 days of registration. Primary outcome is surgical bed recurrence-free survival. Target enrollment is 208 patients. PI is Paul Brown, MD.<\/p>\n

Further information regarding this clinical trial can be obtained from the Alliance website at allianceforclinicaltrialsinoncology.org or clinicaltrials.gov. A list of ongoing trials sponsored by the Alliance can be accessed via the Alliance website.<\/p>\n

The spring Alliance for Clinical Trials in Oncology meeting is a virtual meeting May 3-6, 2023, in Chicago, Illinois.<\/p>\n

 <\/p>\n

NeuroPoint Alliance<\/em><\/p>\n

NPA was established in 2008 to improve quality of care for neurosurgical patients through the acquisition and analysis of clinical outcomes data. The goals of the NPA include:<\/p>\n